Definium Therapeutics is trading at $35.56 (+4.04%) in pre-market, with broad-market strength potentially supporting the move, though no direct link is confirmed. - No fresh company-specific announcement surfaced for October 9; its latest listed press release was September 28. - The supplied market context shows the Nasdaq up 0.86%. - Prior-session biotech weakness is context, not a clear catalyst for this morning’s gain.